Research explains limits of cancer immunotherapy drugs

A new study from the University of Michigan Comprehensive Cancer Center reveals molecular changes within the tumor that are preventing the immunotherapy drugs from killing off the cancer.

Clinical trials with PD-L1 and PD-1 blockade suggested that tumors with a high number of inflammation-causing T cells were more responsive to the immunotherapy-based PD-L1 and PD-1 inhibitors. Tumors with low inflammation, or low T cells, were less responsive. But what controls T cells in the tumor microenvironment is poorly understood.

"We defined a molecular mechanism to explain why some tumors are inflamed and others are not -- and consequently why some patients will be responsive to therapy and others not," says senior author Weiping Zou, M.D., Ph.D.

"If we can reprogram this epigenetic mechanism, then the therapy might work for more patients," says Zou, Charles B. de Nancrede Professor of Surgery, Immunology and Biology at the University of Michigan Medical School.

Zou's group was the first to show PD-L1 expression, regulation and functional blockade in dendritic cells in the human cancer microenvironment.

In this study, published in Nature, researchers studied human and mouse models of ovarian cancer cells. They applied epigenetic drugs and found that the numbers of T cells in the tumor increased. They also saw that the epigenetic drugs synergized the anti-tumor effect of PD-L1 blockade in their models.

"We hope this could be developed into a clinical trial testing a combination of PD-L1 and PD-1 blockade with epigenetic therapy. We want to see if we can make the responders more responsive and turn the non-responders into responders," Zou says.